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Atypical antipsychotic augmentation in SSRI
treatment refractory obsessive-compulsive
disorder: a systematic review and meta-analysis
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Abstract
Background: In 2006, the National Institute of Clinical and Health Excellence (NICE) guidelines for Obsessive
Compulsive Disorder (OCD) recommended anti-psychotics as a class for SSRI treatment resistant OCD. The article
aims to systematically review and conduct a meta-analysis on the clinical effectiveness of atypical anti-psychotics
augmenting an SSRI.
Methods: Studies that were double-blind randomized controlled trials of an atypical antipsychotic against a
placebo, for a minimum of 4 weeks, in adults with OCD, were included. Yale-Brown Obsessive Compulsive Scale
(Y-BOCS) scores were the primary outcome measure. Inclusion criteria included Y-BOCS score of 16 or more and at
least one adequate trial of a SSRI or clomipramine for at least 8 weeks prior to randomization. Data sources included
Medline, Embase, PsycINFO, Cochrane Database of Systematic Reviews (CDSR), trial registries and pharmaceutical
databases and manufacturers up to September 2013. Forest-plots were drawn to display differences between drug
and placebo on the Y-BOCS.
Results: Two studies found aripiprazole to be effective in the short-term. There was a small effect-size for risperidone
or anti-psychotics in general in the short-term. We found no evidence for the effectiveness of quetiapine or olanzapine
in comparison to placebo.
Conclusions: Risperidone and aripiprazole can be used cautiously at a low dose as an augmentation agent in
non-responders to SSRIs and CBT but should be monitored at 4 weeks to determine efficacy.
Keywords: Obsessive compulsive disorder, Anti-psychotic, Selective serotonergic reuptake inhibitor
Background
The National Institute of Clinical and Health Excellence
(NICE) Guidelines for Obsessive Compulsive Disorder
(OCD) in 2006 [1] recommended that for adults with
OCD, with no response to a full trial of at least one
Selective Serotonin Reuptake Inhibitor (SSRI) or clomip-
ramine alone, and a full trial of combined treatment with
Cognitive Behaviour Therapy (CBT) – that includes
exposure and response prevention (ERP) as well as an SSRI,
the following treatment options should be considered: (1)
Additional CBT of increased intensity, (2) Adding an
antipsychotic to an SSRI or clomipramine, (3) Combining
clomipramine and citalopram. No guidance was given on
the order of options. Antipsychotic drugs were recom-
mended as a class and no advice was provided on how to
use an antipsychotic e.g. the dose, duration or potential risk
in the long-term. The recommendation was based on a
meta-analysis of 5 randomized controlled trials (RCTs) of
haloperidol (1 double-blind), risperidone (2 double-blind),
quetiapine (1 single-blind) and olanzapine (1 double-blind)
compared with a placebo and various open-label studies.
The same guidelines did not recommend adding an
antipsychotic to a SSRI for people with Body Dysmorphic
Disorder (BDD) on the basis of one negative trial with
pimozide in those resistant to a SSRI [2]. The NICE
Evidence Update [3] (which summarized the evidence
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published since the NICE guidelines from 2005 to 2013)
included a Cochrane review in 2010 [4] of a meta-
analysis of 11 atypical antipsychotics in OCD, analyzing
only a categorical measure of recovery. Since then, fur-
ther RCTs of antipsychotics have been published.
Current reviews continue to recommend antipsychotic
drugs as a class for augmentation of SSRI treatment re-
sistant OCD [5,6]. It was considered timely to conduct a
new systematic review and meta-analysis given the po-
tential long-term risks of antipsychotics. Furthermore,
off-label prescribing may be particularly vulnerable to
selective data publication, particularly since trials of
such uses have been specifically exempted from industry
pledges on transparency: this can lead to exaggeration
of treatment benefits [7]. A systematic search for un-
published studies was therefore also planned for inclu-
sion. Our question for the systematic review was: “For
adults who have OCD which has failed to respond to at
least one trial of a serotonergic reuptake inhibitor, will
an antipsychotic drug be more effective than a placebo,
in reducing obsessive-compulsive symptoms?” Our sec-
ondary aim was to determine if guidance could be pro-
vided for the order of stepped care, and for the dose and
duration for a trial of an anti-psychotic.
Methods
The review aimed to include any double blind random-
ized study that investigated the effects of an atypical
antipsychotic compared with a placebo for adults with
OCD and which used an intention-to-treat analysis. The
PRISMA method of reporting was used [8].
We excluded haloperidol from the review as, although
it was included in the original meta-analysis by NICE,
there is only one early RCT [9], and of all the antipsy-
chotics it is the most likely to cause extra-pyramidal side
effects or be discontinued for any reason [10]. We focused
on the potential benefits of atypical antipsychotics as
potential harms in the long-term are well documented in
other populations (for example weight gain, metabolic
syndrome, extra-pyramidal symptoms, sedation) [10] and
no long term studies have been conducted in OCD [4].
Eligibility criteria
Studies were included if:
(1) They described adults who had a diagnosis of OCD
according to the DSM or ICD.
(2) They used the Yale-Brown Obsessive Compulsive
Scale (Y-BOCS) [11] as a primary outcome measure.
The Y-BOCS is a 10-item clinician-rated scale which
is widely used to measure the severity of obsessive-
compulsive symptoms, which has a total score
range of 0 to 40. Higher scores indicate greater
symptomatology of OCD.
(3) Participants had persistent symptoms of OCD
defined as a Y-BOCS score of 16 or more.
(4) Participants had had at least one adequate trial of a
SSRI or clomipramine. An adequate trial of a SSRI or
clomipramine was defined as a maximum dose
tolerated for at least 8 weeks prior to randomization.
(5) Participants remained on the SSRI or clomipramine
for the duration of the trial.
(6) They had a trial end point of at least 4 weeks.
No publication date or publication status restrictions
were imposed.
Information sources
Medline, Embase, PsycINFO and Cochrane Database of
Systematic Reviews (CDSR), clinical trial registries and
pharmaceutical databases up to December 2013 were
used to obtain published and unpublished data.
Search
The Medline search strategy used for the NICE guide-
lines was translated into comparable search strategies
for Embase and for previous systematic reviews in the
Cochrane Database (CDSR). We searched all international
clinical trial registries and databases of the pharmaceutical
manufacturers and wrote to the manufacturers to enquire
about any unpublished data of any antipsychotic used in
OCD.
Study selection
A full-text article was retrieved for any citation deemed
relevant by any of the reviewers. All full text articles
were reviewed for inclusion by at least two of the au-
thors. Studies were selected if they fulfilled the eligibility
criteria.
Data collection process
Information was extracted from each included trial on:
(1) The number of participants in each intervention group
(2) Mean (M) and standard deviation (SD) Y-BOCS scores
measured at pre and post drug and placebo intervention
in order to generate related Forest plots.
Two studies provided incomplete data:
(a) For McDougle et al., [12] we calculated the mean
and standard deviation from the raw data provided
and used Last Observation Carried Forward (LOCF)
methodology for three participants whose data were
missing post observation (risperidone M = 19.45,
SD = 8.19 and placebo M = 25.43, SD = 4.58). We
compared the estimates of treatment effect given using
LOCF, to effects calculated after excluding data from
drop-outs. Estimates of treatment effect did not differ
across the methods, therefore LOCF was used for the
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final analysis to ensure intention-to-treat analysis was
used, and that drop-outs were not assumed to behave
in the same way as completers, therefore reducing bias.
(b) Shapira et al., [13] was contacted who provided
the week 8 data for the olanzapine group (M = 19.27,
SD = 3.40) and placebo M = 9.64 SD = 4.14.
We either extracted from all the studies or wrote to
the corresponding author for the (1) Dose range of the
antipsychotic (mg/day), (2) Trial duration of antipsychotic
(in weeks), (3) Current SSRI minimum duration (in weeks)
before randomization and whether participants had re-
ceived the SSRI as part of a double-blind or open-label
trial or part of routine care before commencing the anti-
psychotic drug, (4) Number of previous SSRI trials re-
ceived by participants before recruitment, (5) Number of
previous CBT trials received before recruitment, (5) Inclu-
sion criteria on the Y-BOCS, (6) SSRI treatment resistant
description (see Table 1).
Data item
Our primary outcome of interest was the change in Y-
BOCS score. We calculated difference in means (pre and
post) for each group and entered change-from-baseline
standard deviations calculated by following Cochrane
guidelines on how to impute missing standard deviations.
It was possible to calculate r from the statistics output of
two of the papers included in the meta-analysis [19,22].
The mean of these two r values was then taken, and gave
r = 0.4. Sensitivity analyses testing r = 0.2 and r = 0.6 indi-
cated that as r increased or decreased, the significance of
tests remained the same. Therefore, our Pearson’s r value
from which to compute the change standard deviation
was kept at 0.4, based on previous research. This gave us 3
key variables for each group (drug/placebo), necessary for
computing a meta-analysis and analyzing the effect-sizes
of study outcomes; n in group, mean difference in
Y-BOCS outcome score over the intervention duration,
related change-from-baseline standard deviation. If the
mean Y-BOCS or other information was not available we
contacted the corresponding author of the paper.
All the studies used different definitions of recovery of
either >25% [14,16] or >35% [12,15,17] reduction in Y-
BOCS outcome either with or without additional criteria
such as change on Clinical Global Improvement scale
[12,15]. We therefore confined our categorical analysis
to risperidone studies only since the previous Cochrane
review [4] had conducted this analysis on other anti-
psychotics and there were no new studies for quietapine
and olanzapine.
Risk of bias in individual studies
We assessed the risk of bias at a study level using the
GRADE system [26], which is a systematic and explicit
approach to making judgements about quality of evi-
dence and strength of recommendations.
Summary measure
Our principal summary measures were the difference in
means in the Y-BOCS score from pre to post, and the re-
lated effect-size (Cohen’s D).
Synthesis of results
Analyses were conducted using “metan” and associated
commands in STATA, version 11 [27,28]. The command
combined the outcome of each drug to give an overall
difference on the original Y-BOCS scale (shown along
the x-axis of Figures 1, 2, 3, 4 and 5), summary effect-
size and 95% confidence intervals (C.I.), using a random
effects meta-analysis model of continuous data, with
each study change score weighted by the inverse of the
variance [29]. We used a random effects model as we as-
sumed that the included studies are a random sample of
the population of studies. Forest plots (see Figures 1–5)
were created – each line depicting estimates and confi-
dence intervals for each study, and plotting symbol size
representing the weight of each study entered into the
meta-analysis. Further, as the clinical populations and
treatments had varying factors, we expected treatment
effects to be heterogeneous. For each Forest plot of stud-
ies separated according to antipsychotic trialed, a Z-
score was computed to demonstrate the significance of
the overall effect of a drug in comparison to a placebo.
For investigating the effects of risperidone, a categorical
meta-analysis was also conducted to determine the odds
ratio for responding in comparison to not responding on
the Y-BOCS. One of the studies found 0 responders in
the placebo arm [12]. STATA performs poorly for stud-
ies with a very low or very high event rate and so by de-
fault changes zero frequencies to 0.5 in order to give a
minimum variance unbiased estimate. As this procedure
can influence weighted mean differences, the categorical
analysis has been included for research comparison pur-
poses but is to be considered with caution.
Risk of bias across studies
Heterogeneity across studies was assessed visually with a
Forest plot and statistically with the Q statistic (21) and
I2 statistic. Asymmetry and publication bias of the data
was assessed by a Funnel Plot. However the small num-
ber of studies and participants for each individual drug
made it difficult to interpret [30].
Results
Study selection
Figure 6 provides a flowchart of the search and the num-
ber of studies that were screened for eligibility and sub-
sequently excluded or included in the review. Our
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Table 1 All studies of SSRIs augmented by atypical anti-psychotic in OCD with their characteristics
Study Drug (n) Dose [mg/d] Trial
duration
(weeks)
Current SSRI min. length
(weeks)
Previous SSRIs prior to
recruitment
Previous CBT SSRI treatment resistant description
Placebo (n) (M, SD)
McDougle, 2000 [12] Risperidone (20) 1 - 6 6 12 (open label of a SSRI or
clomipramine)
58.3% had at least 2 trials of SRIs 30% at least 1
trial
≤ 35% improvement or Y-BOCS ≥16 and no
better than score of 3 (minimal improvement)
on CGI to SSRIPlacebo (16) (2.2, 0.7)
Hollander, 2003 [14] Risperidone (10) 0.5 - 3 8 12 (routine care SSRI) 100% had at least 2 trials SRIs 62.5% at least
1 trial
No better than score of 3 (minimal improvement)
on CGI to SSRI. No minimum severity on
Y-BOCS specifiedPlacebo (6) (2.25, 0.86)
Erzegovesi, 2005 [15] Risperidone (10) 0.5 6 12 (open label fluvoxamine) 100% had at least 1 trial of a SRI None 35% or greater improvement or Y-BOCS ≥16 and
no better than score of 3 (minimal improvement)
on CGI to SSRIPlacebo (10) (fixed dose)
Simpson, 2013 [16] Risperidone (20) 0.5 – 4 8 12 (routine care SSRI) 80% had at least 2 trials of SRIs 7% at least 1
trial
All but two had at least minimal improvement
to a SSRI (i.e. some partial responders) and
Y-BOCS ≥16Placebo (40)
CBT (40)
Storch, 2013 [17] Paliperidone (17) 3 - 9 8 12 (routine care SSRI) 100% had at least 2 trials 0% had at
least 1 trial
Not formally assessed but “SSRI had had
minimal effect”. Y-BOCS ≥19
Placebo (17)
Bystritsky, 2004 [18] Olanzapine (13) 5 - 20 6 12 (routine care, SSRI) 100% had at least 2 trials 100% at least
1 trial
No specific criteria
Placebo (13) (11.2, 6.5)
Shapira, 2004 [13] Olanzapine (22) 5 - 10 6 8 40.9% had at least 1 trial of SRI Not known <25% improvement and score of 4 (moderate)
or greater on CGI and Y-BOCS ≥16
Placebo (22) (6.1, 2.1) (open label fluoxetine)
Denys, 2004 [19] Quetiapine (20) 200 8 8 (routine care SSRI) 100% had 2 or more trials 72.5% at least
one trial
< 25% improvement on Y-BOCS to SSRI
and Y-BOCS ≥18
Placebo (20) (Range 100–300)
Carey, 2005 [20] Quetiapine (20) 25 - 300 6 12 (routine care SSRI) Not known Not known < 25% improvement on Y-BOCS or no better
than score of 3 (minimal improvement) on CGI
to SSRI. No minimum Y-BOCS specifiedPlacebo (21) (168.75, 120.82)
Fineberg, 2005 [21] Quetiapine (11) 25 - 400 16 12 (routine care SSRI) Not known Not known < 25% improvement on Y-BOCS to SSRI
and Y-BOCS≥ 18
Placebo (10) (215, 124)
Kordon, 2008 [22] Quetiapine (20) 400 - 600 12 12 (routine care SSRI) 17.5% had two or more trials
82.5% had at least one trial
100% at least
one trial
< 25% improvement on Y-BOCS to SSRI
and Y-BOCS ≥18
Placebo (20)
Diniz, 2011 [23] Quetiapine (18) 50 - 200 12 8 (open label fluoxetine) Most had failed their first
adequate SSRI trial
11% at least 1
trial
<35% improvement on Y-BOCS to SSRI and
Y-BOCS ≥16
Placebo (18) (142, 65)
Clomipramine (18)
Muscatello, 2011 [24] Aripiprazole (20) 15 16 12 (routine care SSRI) Not known Not known Y-BOCS ≥16
Placebo (20) (fixed dose)
Sayyah, 2012 [25] Aripiprazole (21) 10 12 12 (routine care SSRI) Not known Not known Y-BOCS ≥21
Placebo (18) (fixed dose)
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search of trial registries found one published study of
risperidone or placebo with a SSRI in a non-indexed
journal which showed no benefit from adding risperi-
done [31]. However this did not meet our inclusion cri-
teria as participants were not resistant to a SSRI. No
unpublished studies were found from trial registries or
received from manufacturers.
Study characteristics
The characteristics of all studies extracted for inclusion
in the meta-analysis are shown in Table 1.
Risk of bias across the studies
A Funnel plot for all the studies was drawn (Figure 7).
There is some suggestion of asymmetry in the funnel
plot, however as all studies included in the analysis
were small it is difficult to draw a firm conclusion in
terms of small study bias. Asymmetries in funnel plots
can also be due heterogeneity within the sample and
over-estimation of treatment in some studies. Given
this, we would advise caution in any conclusion of
publication bias.
For the GRADE system [26], 4 points was awarded, as
they were all RCTs.
The Quality dimension was rated as “-2”. All of the
trials had a small sample size. There were no long-
term follow up data. Most studies used intention-to-
treat analysis with last observation carried forward
(LOCF) for missing data. However LOCF carries a risk
of bias and variance of treatment effect will be under-
estimated as natural variation in measurement is
factored out [32]. One study used intention to treat
analysis as well as hot-deck imputation [23], and
another used multiple imputation [17] to amend for
missing data. Only multiple imputation is recom-
mended as statistically unbiased way of dealing with
missing data. None of the trials had any self-report
outcome measures of obsessive-compulsive symptoms
or quality of life thus making the conclusions less safe
as blindness may have been compromised.
Consistency was rated as “0”. The I2 and Q values
indicate that there was significant heterogeneity be-
tween the olanzapine trials and the quetiapine trials.
However the small number of trials means that the es-
timate may not be reliable.
Tables 
Published antipsychotic
papers identified: 
(N=46)
Removal of 
duplicates:
(N = 12)
Excluded studies (N=20)
Open label (n = 7)
Metin 2003, Pessina, 2009 Diniz, 2010; D’Amico 2003;
Koran 2000; Liu 2005; Yang 2002
Typical antipsychotic (n = 1)
McDougle 2000
Drug regimen used (n =1)
Pigott 1992
Non SSRI resistant subjects (n = 3)
Connor 2005; Vulink 2009, Tatari 2013
Not placebo controlled (n = 3)
Matsunaga 2011, Selvi 2011,
Single-blind (n = 2)
Atmaca 2001, Maina 2008
Length of trial (n = 1)
Matsunaga 2009; Li 2005
Not randomised (n = 2)
Mohr 2002; Stein 1997
Articles included 
(N = 14)
Risperidone (n = 5)
Olanzapine (n = 2)
Quetiapine (n = 5)
Aripiprazole (n = 2)
Number of studies: (N=34)
Figure 1 Meta-analysis of all anti-psychotics for obsessive-compulsive disorder.
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Directness was rated as “-1”. There were different in-
clusion criteria and dosing of drugs. The populations re-
cruited were narrow in terms of not recruiting those
that failed CBT.
Effect size was rated as “0” as not all effect sizes
were >2 or <0.5 and statistically significant.
The final overall GRADE Score [26] was very low
(score of one or less).
Results of individual studies
A Forest plot was prepared for effect estimates and con-
fidence intervals for anti-psychotics as a class (Figure 1)
Figure 2 Meta-analysis of risperidone treatment vs placebo for obsessive-compulsive disorder.
Figure 3 Meta-analysis of olanzapine treatment vs placebo for obsessive-compulsive disorder.
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and of each drug (risperidone, quetiapine, olanzapine
and aripiprazole in Figures 2, 3, 4, 5). One study evalu-
ated paliperidone, which is the active metabolite of ris-
peridone, and was therefore included with the trials of
risperidone.
Synthesis of results
Fourteen studies with 493 participants (242 atypical anti-
psychotic and 251 placebo) were identified. The overall
mean difference in Y-BOCS score change between drug
and placebo groups was 2.34 points which had an overall
effect-size of D = 0.40 (Figure 1). This is equivalent to
about 10% reduction in Y-BOCS for those taking anti-
psychotics score over time.
The results of the individual atypical anti-psychotics
were as follows:
(a) Risperidone: Five studies were identified
[12,14-17] with 77 participants in total taking
risperidone and 89 receiving placebo. The overall
difference was statistically significant with an
overall mean reduction of 3.89 points on the Y-BOCS
(95% CI = 1.43-5.48) and an effect size of D = 0.53
(Figure 2). The categorical analyses of responders in
comparison to non-responders, on the Y-BOCS,
indicated that overall those participants taking
risperidone were 3.10 times more likely to respond
to treatment (see Figure 8). The number needed to
treat (NNT) for this ratio was 4.65.
(b) Olanzapine: Two studies were identified [13,18]
with 35 participants taking olanzapine and 35 taking a
placebo. The overall difference between olanzapine and
placebo was −0.19, less than one unit point on the Y-
BOCS. This difference was non-significant (Figure 3).
(c) Quetiapine: Five studies were identified [19-23] with
89 participants taking quetiapine and 89 placebo. The
overall difference between quetiapine and placebo was
not significant (0.81 Y-BOCS units) (Figure 4).
(d) Aripiprazole: Two studies were identified [24,25]
with 41 participants taking aripiprazole and 38 taking
placebo. The overall difference between aripiprazole
and placebo was statistically and clinically significant
with a difference in Y-BOCS outcome scores of 6.29
units and overall effect size of D = 1.11 (Figure 5).
Narrative review
(a) Dose
Figure 4 Meta-analysis of quetiapine treatment vs placebo for obsessive-compulsive disorder.
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Within risperidone trials, one study [15] used a very
low fixed dose of risperidone (0.5 mg) and had a better
effect-size than all the studies that used a moderate
dose. This pattern was not possible to identify with
quetiapine studies which used a low to moderate dose
range. Kordon [22] used the highest dose of quetiapine
out of the all quetiapine studies and there was no
significant benefit.
(b) Duration of antipsychotic trial
A variety of end-points were used from 6 weeks to
16 weeks. Six studies [12,13,16,19,20,23] repeated the
Y-BOCS every 1 to 4 weeks before their end-point.
There was no discernible pattern of effect-size on the
length of the trial. Duration of 4 weeks or more did not
seem to make any difference to response. However one
study [23] found that the quetiapine group became
significantly worse between week 4 and week 12.
(c) Duration of SSRI prior to trial
Four studies [12,13,15,23] were preceded by an open-
label study of a SSRI to determine responsiveness prior
to commencing the anti-psychotic trial. The remainder
studies recruited patients who were on a SSRI as part
of their routine care where it may be more difficult to
judge the treatment resistant criteria.
Most studies recruited participants who had been on a
SSRI for 12 weeks. However three studies [13,19,24]
included participants who had been on a SSRI for only
8 weeks. Of these, only one [19] had any significant
benefit from augmentation. A short duration of SSRI
used may be a source of bias in a small study as OCD
may respond to SSRIs gradually with some patients
responding more slowly than others. Of these three
studies, Erzegovesi [15] also investigated effect of
augmenting SRRI responders with risperidone and
found no difference between risperidone and placebo.
(d) Previous CBT
Previous CBT is an integral part of stepped care in the
NICE guidelines. Only four out of the 14 studies
[14,18,19,22] recruited a majority (range 62.5-100%) of
participants who had had a previous trial of CBT. Of
these, two of the four studies found significant benefit.
None of the studies had a trial of CBT as one of their
treatment resistant criteria or had any formal
assessment of the adequacy of such trials.
(e) Treatment refractoriness and SSRI treatment
resistant criteria
There was no discernible pattern in effect-size for the
degree of pharmacological treatment refractoriness (e.g.
Figure 5 Meta-analysis of aripiprazole treatment vs placebo for obsessive-compulsive disorder.
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number of SSRIs) or stringency of SSRI resistant
criteria. All of the studies recruited subjects with a
Y-BOCS of moderate severity in the range of 20 – 30.
Severe symptoms of OCD begin with a Y-BOCS >30.
Studies reporting a higher Y-BOCS scores before
randomization had a larger effect-size for risperidone
[12,14,15] or quetiapine [19] than studies with a
lower Y-BOCS which suggests regression to the mean.
However there were no baseline differences between
the groups in these studies.
(f ) Additional treatment arms
Two studies had an additional treatment arm. Simpson
et al., [16] evaluated CBT as an additional arm and
found that adding CBT was superior to adding either
risperidone or placebo. Diniz et al. [23] found that
adding clomipramine (25-75 mg) to fluoxetine or
adding a placebo to fluoxetine was superior to
quetiapine use. However in this study, for participants
taking 60-80 mg, the dose of fluoxetine was reduced to
avoid interaction with clomipramine.
(g) Follow up
None of the studies had any long-term follow-up for
outcome or adverse events after their end point. One
study [33] (which was excluded from the meta-analysis as
it was a follow up study with a variety of anti-psychotics)
compared participants who had responded to a SSRI plus
CBT for 1 year. Subjects who failed to respond to a SSRI
were randomly assigned to quetiapine, risperidone or
olanzapine plus CBT. At 1-year follow-up, augmentation
with CBTand an antipsychotic was associated with a
drop of 10 points on the Y-BOCS. However their
Y-BOCS remained significantly higher compared to
the SSRI responders after 1 year and both groups had
received CBT. Fifty per-cent of subjects on the
antipsychotic had an increase of >10% in their Body Mass
Index (BMI) and a higher fasting blood sugar compared
to 15.2% with raised BMI in the SSRI responders.
(h) Differences in pharmacodynamics
The anti-psychotic, haloperidol (which is highly
selective for D2 receptors) was shown to be effective
against a placebo in one early study [9], which
achieved Y-BOCS change of 5 units compared to
placebo with an effect size of D =1.06. Aripiprazole is
the most atypical (in terms of effects on D2, 5HT-1A
and 2A, and 5HT-C receptors) and also showed a
similar effect size of 6 units over placebo. Thus there
dos not appear to any specific pharmacodynamics
effect of anti-psychotics in OCD and that the
differences between studies are more likely to occur
because of the heterogeneity within OCD.
Figure 6 Flow diagram of study selection for meta-analysis.
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(i) Non-Responders by symptom sub-type
No studies specifically report excluding hoarders,
which is now recognized as a separate disorder in
DSM-5 and generally has a worse prognosis with any
treatment. Two studies [12,19] attempted to classify
their participants according to predominant symptom
subtype (for example the dimensions of checking;
symmetry, order, counting and repeating; contamination
and cleaning; hoarding) [34]. Certain symptom sub-types
might do better or worse with a treatment although
sub-types often overlap and vary in severity. As yet
there is no identified genotype or phenotype to
determine predictors of outcome with an anti-psychotic
augmentation in OCD.
(j) Tic disorder
The original study on haloperidol [12] found benefit in
those with comorbid tics compared to those without.
In this meta-analysis, two studies found no difference
in response between those with or without co-morbid
tics [12,20]. In all other studies, no analyses were made
of co-morbid tics either because of the small numbers
or no assessment was made.
Discussion
This systematic review and meta-analysis found evidence
for the benefit with a modest effect size for aripiprazole
in the short term in people with OCD who were resist-
ant to at least one SSRI. Risperidone or anti-psychotics
as a class had a statistically significant benefit in the
short term but with a weaker effect size. There was no
evidence for the clinical effectiveness of olanzapine or
quetiapine. The overall GRADE of the recommendations
of anti-psychotics in OCD was very low [26].
The strength of this study is that it is an up to date sys-
tematic review and meta-analysis of antipsychotic aug-
mentation in OCD since the publication of five recent
RCTs. It was conducted using a thorough search of pub-
licly accessible databases, and by requesting unpublished
studies from pharmaceutical companies. A number of
possible biases were identified that may result in an over-
estimate of treatment benefits or difficulties in generaliz-
ing to the population of treatment refractory OCD.
The heterogeneity and weakness of the effect size of
anti-psychotics as a class may be because of the hetero-
geneous nature of OCD, different populations recruited
Figure 7 Funnel plot for all studies.
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and small sample sizes. Thus it may be that there is a
sub-group of people with OCD who may respond to any
anti-psychotic as a class effect – the problem is at
present there is no way of identifying “responders” be-
fore a trial.
Although we found benefit for aripiprazole and risperi-
done, this should be weighed against unknown benefit
and potential physical risks in the long term. Aripipra-
zole is limited to two recent studies. Thus it would be
particularly important to conduct large studies of aripi-
prazole in participants who have failed at least one SSRI
and CBT to determine effectiveness in the long term.
However it may not be particularly helpful to conduct
further trials of other anti-psychotics in OCD until bio-
psychosocial markers can identify the minority who may
respond. Furthermore it would be helpful if researchers
could agree to treatment resistant criteria before entry
into such a trial. Psychopharmacologists prefer different
percentage changes on the Y-BOCS [35] whilst cognitive
behaviour therapists tend to use the Jacobson & Truax
[36] index of "reliable and significant change" and to
complement the YBOCS with subject rated symptom
and quality of life measures.
Alternative augmentation strategies may be more ef-
fective than an antipsychotic and safer in the long term.
For example, from a study in this meta-analysis, Simp-
son et al., [16] found that adding CBT was superior to
adding either risperidone or placebo. Diniz et al., [23]
found that adding clomipramine 25-75 mg to fluoxetine
was superior to quetiapine and fluoxetine. Another ran-
domised open-label trial found that citalopram with clo-
mipramine was superior to citalopram alone [37]. These
studies have possible implications for recommending the
order of treatments in the stepped care of OCD: for
adults with OCD on a SSRI there is an argument for a
more intensive trial of CBT before a trial of anti-
psychotic. Another alternative is combining citalopram
or escitalopram with a low dose of clomipramine with
ECG monitoring of the QTc interval. Caution would be
required combining fluoxetine with clomipramine be-
cause of interactions on the hepatic cytochrome P450
iso-enzymes. This can potentially lead to an increase of
Figure 8 Meta-analysis of risperidone treatment vs placebo for obsessive-compulsive disorder, measured as odds ratios.
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clomipramine so that plasma clomipramine levels and
ECG monitoring would be required. It is not known
whether combining a SSRI with clomipramine would be
equally effective as increasing the SSRI to a supra-
maximal dose with serum level and ECG monitoring [38].
The area in which there is least knowledge for treat-
ment algorithms is for people with OCD with severe
symptoms who have been resistant to at least 2 trials of
SSRI or clomipramine for a minimum of 12 weeks at
maximum tolerated dose and two trials of CBT, which
has been competently delivered. None of the current
studies had a trial of even one CBT as one of their treat-
ment resistant criteria for entry into their trial or had
any formal assessment of the adequacy of such trials. A
combination of SSRI and CBT can augment the effect-
size in severe OCD. However it is not known if a SSRI
with an antipsychotic can augment or even diminish the
effect of CBT.
The clinical implications are that if aripiprazole or ris-
peridone is used in severe treatment resistant OCD, then
to determine effectiveness it should be a trialled for no
longer than 4 weeks and without any other interventions
such as CBT to determine effectiveness. Erzegovesi [15]
also found that there was no difference to augmenting
SRRI responders with risperidone and placebo. Thus for
patients who have had a response to a SSRI (but are
usually still symptomatic), they may not obtain any extra
benefit from adding risperidone.
For risperidone a low dose of 0.5 mg or for aripipra-
zole 10 mg (or possibly lower) may be recommended in
those who have not responded to two trials of SSRI or
CBT. If a patient is judged to be a responder at 4 weeks
then a full discussion should be had with the patient on
the possible long-term adverse risks and the need for
regular monitoring of weight, blood sugar and lipid
profile. Audits of referrals of patients with OCD on anti-
psychotics at our specialist service suggest that outcome
monitoring at 4 weeks or physical monitoring in the
long term are rarely conducted.
Conclusions
In summary, we found limited evidence for low dose ris-
peridone and aripiprazole in the short-term. Aripiprazole
is associated with less risk of weight gain, sedation, and
increase in prolactin compared to other antipsychotics
[10]. We do not recommend the use of olanzapine or
quetiapine to augment SSRIs in OCD. There is some
evidence for augmenting a SSRI with CBT or clomipra-
mine before an anti-psychotic. However a combination
with clomipramine requires ECG monitoring. The defin-
ition of treatment resistance should include at least one
adequate trial of CBT. Studies of augmentation of a SSRI
with aripiprazole should be followed up in the long-
term.
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